

Special Issue

Cellular and Molecular Mechanisms that Control and Regulate Immune Responses after Liver Transplantations

Message from the Guest Editors

The era of success in solid organ transplantation started with the clarification of the immunologic mechanisms that govern graft rejection and induction of immune tolerance. The advent of immunosuppressive therapy resulted in sustained prolonged graft and patient survival. Cellular and humoral rejection in liver transplantation is a factor that threatens long-term graft survival. Although there are many research teams around the world working on the mechanisms of immune responses in liver transplantation, the majority of transplantation research mainly focuses on the technical aspects of the procedure. It is our opinion that all the research in the field of transplant immunology should be concentrated on a single or a series of concise contemporary issues. Together with this objective in mind, we invite colleagues around the world to submit their basic science and original research studies and review articles to this Special Issue. We welcome molecular and basic science research as well as clinical observations and experiences in the field.

Guest Editors

Prof. Dr. Sami Akbulut

Department of Surgery, Public Health and Biostatistics and Medical Informatics, Inonu University Faculty of Medicine, Elazig Yolu 10. Km, Malatya 44280, Turkey

Prof. Dr. Tevfik Tolga Şahin

Liver Transplant Institute, Inonu University Faculty of Medicine, 44000 Malatya, Turkey

Deadline for manuscript submissions

closed (31 March 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/137768

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).